European Heart Journal (2002) 23 (Abstract Supplement), xi–xvi
Contents Programme number (P = poster)
Page
AbstractSelection ......................................................................................................
iii
Abstract Review Committee ............................................................................................
vii
Abstracts ..............................................................................................................
1
Day 2— Sunday 1 September 2002 Resynchronisation therapy in heart failure: are we doing any good? ........................................... Catheter ablation of ventricular tachycardia ................................................................. Arrhythmogenic right ventricular cardiomyopathy ........................................................... Implantable cardioverter-defibrillators in primary and secondary prevention .................................... Mechanisms for modulation of vascular function in type II diabetes ........................................... Aortic dissection ......................................................................................... Lesion severity: our eyes are not good enough! .............................................................. Any progress on coronary flow and myocardial perfusion? .................................................... Young Investigators' Award Session (Basic Science) ......................................................... Lipid modulating therapy: benefits and disavantages ......................................................... Effects of new and established lipid-lowering drugs .......................................................... Tissue factor: let's go for pathways ......................................................................... Degenerative aortic stenosis, new mechanisms .............................................................. Facilitated and rescue percutaneous coronary intervention in acute myocardial infarction ........................ The spectrum of infective endocarditis ...................................................................... Success of coronary stenting: is imaging needed? ............................................................ Adding new drugs to baseline treatment in heart failure ...................................................... Current initiatives in cardiac surgery in the management of heart failure ....................................... Prognosis in heart failure: predictors of outcome ............................................................ Refined Doppler indices for assessing diastolic function ...................................................... European Society of Cardiology Lecture on Clinical Cardiology .............................................. Added value of stress echo in patients with chest pain ........................................................ Computer demonstration .................................................................................. Moderated Poster Session I ................................................................................ Long-term biventricular pacing results ...................................................................... Arrhythmias mechanisms: cellular electrophysiology and pathophysiology ..................................... Atrial fibrillation: pacing and technical aspects .............................................................. Inflammatory injury of the vessel wall ...................................................................... Lipids and atherosclerosis ................................................................................. Angiogenesis ............................................................................................ Tissue Doppler imaging ....................................................:.............................. Coronary circulation ....................................................................................... Congenital heart disease in grown up ....................................................................... Evaluation of the results of cardiac surgery ................................................................. Exercise testing/Micellaneous topics ....................................................................... The periphery in chronic heart failure ...................................................................... Myocardial function in heart failure ........................................................................ Peripheral circulation ..................................................................................... Myocardial infarction – Prognosis assessment ............................................................... Platelet function and biochemistry ......................................................................... Computers in cardiology .................................................................................. Genetic and diagnostic aspects in hypertrophyc cardiomyopathy .............................................. Resuscitation and autonomic external defibrillator ........................................................... Update on cellular effects of lipoproteins ................................................................... Altered hearts harbour altered genes ........................................................................ Reperfusion injury during cardiac surgery .................................................................. Carotid stenting .......................................................................................... Imaging the coronary artery: are the new techniques competitors or adjuncts to angiography? .................... New pathways of endothelial cell modulation ............................................................... Molecular studies in atherosclerosis ........................................................................ Clinical correlates in alterosclerosis ........................................................................
3 4 5 7 8
10 12 14 16 17 18 20 21 23 24 26 28 29 31 32 34 35 37 37 40 41 48 52 54 56 57 64 73 76 77 85 91 95 102 112 115 119 122 124 125 127 128 130 131 133 134
Downloaded from http://eurheartj.oxfordjournals.org/ by guest on January 22, 2017
77-81 104-109 114-119 120-125 169-174 175-180 185-190 191-196 200-204 205-210 211-216 217-222 223-227 255-260 274-279 280-285 286-291 292-297 303-308 324-329 331-333 334-339 345-346 P347–P356 P357–P361 P362–P390 P391–P404 P405–P411 P412–P418 P419–P425 P426–P449 P450–P485 P486–P498 P499–P503 P504–P533 P534–P556 P557–P567 P568–P598 P599–P634 P635–P643 P644–P661 P662–P672 714-719 755-760 761-766 771-776 777-782 783-788 789-794 795-800 801-806
xii
Contents
Cost-effectiveness of cardiovascular interventions ........................................................... Fundamental aspects of atrial fibrillation .................................................................... Atrial fibrillation burden reduction by pacing ................................................................ We are still on the way: drug eluting and coated stents ....................................................... Drug eluting stents: options beyond sirolimus? .............................................................. Cardiac computed tomography: something new on the horizon? ............................................... Stratification in coronary artery disease: use of myocardial imaging ........................................... Myocarditis: diagnostic aspects ............................................................................ New issues in hypertrophic cardiomyopathy ................................................................ Magnetic resonance imaging in cardiac arrhythmias: a new alliance? .......................................... Magnetic resonance imaging in cardiology: routine or still new? .............................................. Computer demonstration .................................................................................. Moderated Poster Session II ............................................................................... Pacing – Complications and technical aspects ............................................................... Catheter ablation – Ventricular tachycardia .................................................................. Electrocardiogram in Brugada's syndrome, Wolff–Parkinson–White's syndrome and other clinical conditions ..... Diabetes and atherosclerosis ............................................................................... Cardiovascular control mechanisms in health and disease ..................................................... Inflammatory mechanisms of cell damage .................................................................. Imaging of atherosclerosis ................................................................................ Transoesophageal echocardiography valvular heart disease ................................................... Magnetic resonance imaging: what's new? .................................................................. Restenosis and genetics ................................................................................... Paediatric cardiology, others ............................................................................... Epidemiology and prevention miscellaneous ................................................................ Hypertension, other risk factors and cardiovascular disease ................................................... Experimental heart failure ................................................................................. Experimental studies in heart failure ....................................................................... Assessing viable myocardium: current perspectives .......................................................... Treatment of hypertension ................................................................................. Myocardial ischaemia – Experimental studies ............................................................... Thrombosis – Endothelial function ......................................................................... Myocardial infarction – Insights to pathophysiology ......................................................... Gene delivery to cardiac tissues ............................................................................ New insights in dilative cardiomyopathy ....................................................................
Day 3 1277-1282 1288-1293 1294-1299 1305-1310 1311-1316 1340-1345 1346-1351 1356-1361 1362-1367 1368-1373 1374-1379 1380-1385 1386-1391 1392-1397 1398-1403 1412-1416 1432-1436 1446-1451 1452-1456 1458-1463 1464-1469 1470-1475 1476-1481 1505-1510 1512-1514 1525-1526
—
136 138 139 141 142 144 145 147 149 150 151 153 154 156 162 164 168 172 174 175 176 182 185 189 192 197 199 204 205 208 214 221 225 229 230
Monday 2 September 2002
Arrhythmias mechanisms ................................................................................. Stroke in patients with atrial fibrillation ..................................................................... Cardiac and peripheral metabolic effects of pacing ........................................................... Prevention, diagnosis and intervention: the impact of nursing in patient care .................................... Percutaneous interventions in valvular heart disease ......................................................... Endogenous mechanism in myocardial protection ........................................................... Cardiac adaptation and dysfunction in hypertension: from models to patients ................................... New features of coronary bypass surgery ................................................................... Variables influencing coronary flow: do we know them all? ................................................... Restenosis research: still worth the effort ................................................................... Subcellular regulation of myocardial contractility ............................................................ Molecular mechanisms of atherosclerosis from mouse to man ................................................. Pulmonary veins in atrial fibrillation: from anatomy to ablation ............................................... Myocardial diseases ...................................................................................... Psychosocial consequences of cardiovascular disease ........................................................ Modulation of atherosclerotic plaque inflammation .......................................................... Young Investigators' Award Session (Thrombosis) ........................................................... Coronary revascularisation: needle or knife? ................................................................ Drug eluting stents: are they still holding their promise? ...................................................... Thrombolysis ............................................................................................ New devices for interventions in acute myocardial infarction ................................................. BNP in heart failure: predictors of outcome ................................................................. Determinants of long-term prognosis in heart failure ......................................................... Assessment of left ventricular function by tissue Doppler ..................................................... European Society of Cardiology Lecture on Clinical Cardiology .............................................. Computer demonstration ..................................................................................
237 238 240 241 243 244 246 248 249 251 252 254 255 257 258 260 261 263 264 266 267 269 271 273 274 275
Downloaded from http://eurheartj.oxfordjournals.org/ by guest on January 22, 2017
807-812 813-818 819-824 861-866 867-872 873-878 879-884 885-890 891-895 915-919 921-926 937-938 P939–P948 P949–P970 P971–P980 P981–P993 P994–P1010 P1011–P1017 P1018–P1023 P1024–P1026 P1027–P1051 P1052–P1059 P1060–P1075 P1076–P1088 P1089–P1109 P1110–P1117 P1118–P1134 P1135–P1140 P1141–P1152 P1153–P1172 P1173–P1200 P1201–P1215 P1216–P1232 P1233–P1238 P1239–P1250
Contents
Moderated Poster Session III .............................................................................. Atrial fibrillation Ablation, mechanisms .................................................................. Atrialarrhythmias ........................................................................................ Syncope ................................................................................................. Atrial fibrillation — Electrical cardioversion ................................................................. Inflammation in atherosclerosis ............................................................................ Cellular biology of myocardial protection ................................................................... Influence of gene polymorphisms .......................................................................... Oxidation and atherosclerosis .............................................................................. Contrast echocardiography and tissue characterisation ....................................................... Comparative myocardial imaging .......................................................................... Percutaneous coronary intervention outcomes ............................................................... Paediatric cardiology/others ............................................................................... Diabetes and cardiovascular disease ........................................................................ Nutrition, alcohol and cardiovascular risk ................................................................... Drug therapy in heart failure ............................................................................... Calcium and signal transduction ........................................................................... Diastolic function in heart failure .......................................................................... Neuro-hormonal control mechanisms in heart failure ......................................................... Cardiac and vascular alterations in hypertension ............................................................. Direct percutaneous coronary intervention in acute myocardial infarction ...................................... Interventions after myocardial infarction .................................................................... Cardiovascular diseases in the 21st century: the challenges for nurses .......................................... Myocarditis and pericarditis ............................................................................... Arrhythmogenic right ventricular cardiomyopathy ........................................................... Implantable cardioverter-defibrillator — technical aspects ..................................................... Syncope — Tilt test and long-term outcome .................................................................. Smoking in patients with ischaemic heart disease: risk assessment and treatment ................................ The vessel wall as a target of hypertension .................................................................. The ups and downs of endothelial function .................................................................. Long-term results of value surgery ......................................................................... Cardiovascular diseases in the young: consequences later on .................................................. Characterization of the vulnerable plaque by heat, elasticity or morphology .................................... Drug effects in experimental heart failure ................................................................... Non-lipid-lowering effects of statins ........................................................................ Genetics in atherosclerosis ................................................................................ Stunning, hibernation, preconditioning ..................................................................... Monitoring atrial septal defect closure by echocardiography .................................................. Inflammation, cytokine and heart failure .................................................................... Can we build a new heart from stem cells? .................................................................. Gene therapy in coronary and myocardial disease ............................................................ European Society of Cardiology Lecture on Basic Sciences ................................................... ............................. New cardiac markers .......................... Primary percutaneous coronary intervention in acute myocardial infarction ..................................... Percutaneous coronary intervention: variations in stenting, cutting and spotting ................................. Percutaneous coronary interventions: whom to treat or not to treat ............................................. Primary stenting in acute myocardial infarction. Percutaneous coronary intervention versus thrombolysis ......... Percutaneous coronary intervention in acute coronary syndromes ............................................. Genetics of dilated cardiomyopathy ........................................................................ Results from recent clinical trials: implications for drug therapy in practice ..................................... From perfusion assessment to clinical decision making: the role of contrast echocardiography .................... Improved assessment of myocardial ischaemia by tissue Doppler .............................................. Computer demonstration .................................................................................. Moderated Poster Session IV .............................................................................. Cellular electrophysiology ................................................................................ Non-invasive risk stratification ............................................................................. Atrial fibrillation — Stroke ................................................................................. Resynchronization therapy in heart failure patients: predicting factor of success ................................ Predictors of atherosclerosis ............................................................................... Lipid-lowering drugs ..................................................................................... Infection in atherosclerosis ................................................................................ Neurohumoral control mechanisms in health and disease ..................................................... Congenital heart disease, right heart and miscellaneous ...................................................... —
..............................I
276 278 282 284 287 290 293 295 297 298 303 305 312 316 321 324 328 329 331 334 338 345 350 352 355 357 359 360 362 363 365 366 368 369 371 373 375 376 378 379 380 382 383 384 386 388 389 391 393 394 396 398 400 401 403 405 411 412 414 417 422 424 425
Downloaded from http://eurheartj.oxfordjournals.org/ by guest on January 22, 2017
P1527—P1536 P1537—P1549 P1550—P1559 P1560—P1569 P1570—P1583 P1584—P1596 P1597—P1603 P1604—P1609 P1610—P1613 P1614—P1633 P1634—P1642 P1643—P1665 P1666—P1683 P1684—P1698 P1699—P1708 P1709—P1723 P1724—P1728 P1729—P1735 P1736—P1747 P1748—P1763 P1764—P1790 P1791—PI808 P1809—P1818 P1819—P1830 P1831—P1836 1889-1894 1895-1900 1922-1926 1936-1940 1942-1947 1948-1953 1954-1959 1960-1964 1966-1971 1972-1977 1978-1983 1984-1988 1989-1994 1995-2000 2009-2013 2021-2026 2032-2034 2035-2040 2041-2046 2047-2052 2053-2058 2059-2064 2065-2070 2071-2076 2077-2082 2099-2104 2105-2110 2119-2120 P2121—P2129 P2130—P2137 P2138—P2158 P2159—P2165 P2166—P2172 P2173—P2184 P2185—P2204 P2205—P2211 P2212—P2216 P2217—P2234
xiii
xiv
Contents
P2235-P2244 P2245-P2262 P2263-P2267 P2268-P2270 P2271 -P2277 P2278-P2291 P2292-P2300 P2301-P2316 P2317-P2324 P2325-P2333 P2334-P2347 P2348-P2372 P2373-P2393 P2394-P2402 P2403-P2414 P2415-P2422
Novel approaches in myocardial scintigraphy ............................................................... Percutaneous coronary intervention: adjunctive therapy, complications ......................................... Paediatric catheter intervention ............................................................................ Fetal cardiology .......................................................................................... Risks of cardiac surgery ................................................................................... Cardiac rehabillitation .................................................................................... Cardiovascular disease in the elderly ....................................................................... Prognosis in heart failure .................................................................................. Heart transplantation ..................................................................................... Diastolic function in heart failure .......................................................................... Pathophysiology of hypertension ........................................................................... Endothelial function ...................................................................................... Biomarkersinischaemia/infarction ......................................................................... Nursing roles in heart failure management: meeting the needs of patient and carers ............................. Miscellaneous myocardial diseases ......................................................................... Valve disease - Miscellaneous .............................................................................
430 433 437 438 439 441 445 447 452 454 456 460 466 472 474 477
2515-2519 2521 -2526 2527-2532 2533-2537 2559-2564 2565-2570 2571 -2576 2577-2582 2593-2598 2599-2604 2613-2618 2619-2623 2625-2630 2631 -2636 2661 -2665 2677-2682 2683-2688 2689-2694 2695-2700 2701-2706 2726-2731 2733-2735 2740-2744 2746-2747 P2748-P2756 P2757-P2778 P2779-P2792 P2793-P2799 P2800-P2809 P2810-P2820 P2821-P2829 P2830-P2833 P2834-P2837 P2838-P2864 P2865-P2893 P2894-P2899 P2900-P2908 P2909-P2921 P2922-P2931 P2932-P2940 P2941-P2964 P2965-P2972 P2973-P2978 P2979-P2991 P2992-P3015
Day 4 Tuesday 3 September 2002 Familial arrhythmias: the door to the genetic basis of sudden death ............. ............................... Catheter ablation of ischaemic ventricular tachycardia ........................ ............................... Drug treatment of atrial fibrillation .......................................... ............................... Young Investigators' Award Session (Clinical Science) ........................ ............................... Pulmonary hypertension ................................................... ............................... Clinical relevance of circadian variations of blood pressure and heart rate ....... ............................... Endothelial dysfunction: new targets? ....................................... ............................... The "active" platelet ....................................................... ............................... Advances in hypertension management ...................................... ............................... Progress in prevention of stroke ............................................. ............................... The many facets of vessel wall maintainancy ................................. ............................... Signal transduction pathways in cardiac hypertrophy and failure ............... ............................... Revascularization therapy in the elderly ..................................... ............................... Genders differences in the diagnosis and treatment of cardiovascular disease ................................... Progressive new strategies for the treatment of myocardial infarction ........... ............................... Outcomes after percutaneous coronary intervention: the challenge remains ...... ............................... Impact of the redefinition of myocardial infarction ............................ ............................... Antiplatelet therapy - Risks and benefits ..................................... ............................... Management of patients after heart transplantation ............................ ............................... Beta blocker therapy in heart failure: current thoughts ......................... ............................... New developments in three-dimensional echocardiography .................... ............................... European Society of Cardiology Lecture on Population Sciences ............... ............................... New ultrasound techniques to understand cardiovascular function .............. ............................... Computer demonstration ................................................... ............................... Moderated Poster Session V ................................................ ............................... Pulmonary vein ablation in atrial fibrillation ................................. ............................... Biventricular pacing and heart failure ........................................ ............................... Signal averaged electrocardiogram .......................................... ............................... Sudden death - Resuscitation ............................................... ............................... Growth factors and cell proliferation in atherosclerosis ........................ ............................... Genetics in atherosclerosis ................................................. ............................... Stem cells: methodology ................................................... ............................... Contractile function ....................................................... ............................... Stress echocardiography ................................................... ............................... Interventional cardiology ................................................... ............................... Paediatric arrhythmia/electrophysiology ..................................... ............................... Update on surgical techniques .............................................. ............................... Cardiovascular disease in women ........................................... ............................... Lipids (epidemiology) ..................................................... ............................... Cardiac rehabilitation ...................................................... ............................... Brain natriuretic peptide in heart failure management ......................... ............................... Exercise training in heart failure ............................................ ............................... Diagnosis and monitoring of heart failure .................................... ............................... Pulmonary circulation ..................................................... ............................... Myocardial ischaemia/infarction ............................................ ...............................
483 484 486 487 489 491 492 494 496 497 499 501 502 504 505 507 508 510 511 513 515 516 517 519 519 522 527 531 533 536 538 540 541 542 550 558 559 561 565 567 569 576 578 580 583
—
Downloaded from http://eurheartj.oxfordjournals.org/ by guest on January 22, 2017
xv
P3016-P3036 P3037-P3041 P3042-P3051 P3052-P3056 3197-3198
Endothelial function ...................................................................................... Drug therapy in heart failure ............................................................................... Aortic valve stenosis ...................................................................................... Valve protheses .......................................................................................... Computer demonstration ..................................................................................
590 595 597 600 601
3213-3218 3219-3223 3228-3233 3247-3252 3253-3258 3259-3264 3265-3270 3271-3276 3277-3282 3283-3288 3289-3294 3295-3300 3301-3306 3307-3312 3313-3318 3319-3324 3333-3338 3339-3343 3344-3349 3350-3355 3356-3361 3362-3367 3368-3373 3374-3379 3380-3385 3386-3391 3392-3397 3398-3403 3416-3421 3422-3427 3432-3437 P3438-P3446 P3447-P3465 P3466-P3481 P3482-P3491 P3492-P3500 P3501-P3508 P3509-P3513 P3514-P3518 P3519-P3536 P3537-P3547 P3548-P3562 P3563-P3579 P3580-P3588 P3589-P3593 P3594-P3604 P3605-P3614 P3615-P3621 P3622-P3634 P3635-P3639 P3640-P3648 P3649-P3658 P3659-P3664 P3665-P3685 P3686-P3707 P3708-P3713
Day 5—Wednesday 4 September 2002 Pulmonary vein isolation in artificial fibrillation ............................................................. New trends in imaging .................................................................................... Catheter ablation in atrial fibrillation - Linear lesions ........................................................ Diabetes and cardiovascular disease ........................................................................ Vascular structure and function ............................................................................ New aspects of neurohormonal regulation in hypertension .................................................... Left ventricular remodelling after myocardial infarction ...................................................... Trends in cardiovascular disease in Europe .................................................................. The role of assist devices in heart failure .................................................................... Management of congenital heart disease in grown-ups ....................................................... Congenital heart disease: metabolism and arrhythmias ....................................................... Interventional cardiology in congenital heart disease ......................................................... Prognosis of acute myocardial infarction: registries versus studies ............................................. Pericarditis .............................................................................................. Prognostic factors for cardiovascular disease in healthy populations ........................................... Benefits of cardiac rehabilitation ........................................................................... Growth factor regulation of cardiac size .................................................................... Novel mechanisms in the control of cardiac function ......................................................... Left ventricular dysfunction: insights from transgenic mice ................................................... Molecular mechanisms of myocardial ischaemia ............................................................ Thrombolytic "cocktails" - Beneficial or dangerous .......................................................... Glycoprotein IIb/IIIa - New aspects ........................................................................ Percutaneous coronary intervention in 2002: achievements, however, some darkness remains! .................... Exploiting the potentials of coronary flow reserve ........................................................... Electrocardiogram and prognosis in heart failure ............................................................ New markers of heart failure .............................................................................. Neurohormonal mechanisms in heart failure: current perspectives ............................................. Angiotensin-converting enzyme inhibitors and A2 blockers: Roles in heart failure therapy ....................... Conduction disturbance and ventricular function ............................................................. Innovating applications of transoesophageal echocardiography ................................................ New markers for stress-induced ischaemia .................................................................. Moderated Poster Session VI .............................................................................. Atrial fibrillation treatment ................................................................................ Implantable cardioverter-defibrillator Clinical and technical aspects .......................................... Atrial flutter - Ablation ................................................................................... Control mechanisms in myocardial hypertrophy ............................................................. Gene polymorphism in coronary artery disease .............................................................. Gene expression .......................................................................................... Animal models in atherosclerosis .......................................................................... Doppler echocardiography ................................................................................ Cardiac metabolism ...................................................................................... Coronary angiography .................................................................................... Brachytherapy, coated stents ............................................................................... Paediatric catheter intervention ............................................................................ Cardiac surgery - Miscellaneous ........................................................................... Atherosclerosis and coronary heart disease .................................................................. Smoking and its effects on the cardiovascular system ........................................................ Primary prevention ....................................................................................... Beta blockers in heart failure .............................................................................. Prevalence and population surveys in heart failure ........................................................... Cardiac assist devices ..................................................................................... Therapeutic interventions for heart failure .................................................................. Stroke ................................................................................................... Left ventricle after infarction: remodelling, perfusion, function ................................................ Antithrombotic/thrombolytic agents ........................................................................ Drug effects on blood coagulation and vessels ...............................................................
605 606 608 609 611 612 614 616 618 620 622 623 625 627 628 630 631 633 634 636 637 639 641 643 644 646 647 649 651 652 654 656 658 663 667 669 672 674 675 676 681 684 688 692 695 696 699 701 703 707 708 710 713 715 721 727
-
Downloaded from http://eurheartj.oxfordjournals.org/ by guest on January 22, 2017
Contents
xvi
Contents
P3714—P3730 Social aspects of cardiovascular disease .................................................................... P3731—P3739 Transcoronary ablation in hypertrophic cardiomyopathy ...................................................... P3740—P3748 Mitral valve disease ......................................................................................
728 733 735
AuthorIndex ..........................................................................................................
739
Indexof Topics .........................................................................................................
783
Downloaded from http://eurheartj.oxfordjournals.org/ by guest on January 22, 2017
This abstract book has been produced electronically by CONIFERTM, Excerpta Medica Medical Communications b.v. and is also available as a fully searchable service at the Congress and on CD-ROM. Every effort has been made to faithfully reproduce the abstracts as submitted. However, no responsibility is assumed by the organisers for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of the rapid advances in the medical sciences, we recommend that independent verification of diagnoses and drug dosages should be made.
